Bolt Biotherapeutics (BOLT) Accumulated Expenses (2020 - 2026)

At the end of FY2025, Bolt Biotherapeutics reported Accumulated Expenses of $3.72 million, down 59.1% from FY2024.

• Annual Accumulated Expenses has declined for three straight years, with a five-year compound annual growth rate of -11.0% (FY2020 to FY2025).
• Across earlier years, Accumulated Expenses came in at $9.08 million in FY2024 (-27.3%), $12.49 million in FY2023 (-17.5%), $15.14 million in FY2022 (+22.3%) and $12.38 million in FY2021 (+85.9%).
• Quarterly Accumulated Expenses has ranged from $2.02 million in Q1 2026 to $15.14 million in Q4 2022 over the past five years.
• On a year-over-year basis, Accumulated Expenses has declined for seven consecutive quarters, with an average decline of 41.6% over the last eight quarters.
• Peak year-over-year performance for Accumulated Expenses in the last five years was growth of 85.9% in Q4 2021, against a decline of 69.1% in Q1 2026 at the low end.
• Per Business Quant, the preceding three quarters came in at $2.02 million (Q1 2026), $3.72 million (Q4 2025) and $3.84 million (Q3 2025).